<DOC>
	<DOC>NCT00524810</DOC>
	<brief_summary>Evaluation of safety and efficacy of a treatment associating Pegylated Liposomal Doxorubicin + Docetaxel in patients with metastatic breast cancer</brief_summary>
	<brief_title>Liposomal Doxorubicin and Docetaxel in Metastatic Breast Cancer</brief_title>
	<detailed_description>Evaluation of safety and efficacy of a treatment associating Pegylated Liposomal Doxorubicin + Docetaxel in patients with metastatic breast cancer. Patients will receive pyridoxin to prevent cutaneo-mucinous toxicities.</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<criteria>first metastatic chemo line presence of measurable or bone lesion at least one lesion outside the radiated areas can have previously received hormonotherapy, chemotherapy in adjuvant phase, radiotherapy if older than 4 weeks only local tumoral progression symptomatic cerebral metastasis neuropathy &gt; NCICTC 2 previous cancer within 10 years _ previous cancer within 10 years</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2011</verification_date>
</DOC>